Follow
Almer van der Sloot
Almer van der Sloot
Verified email at umontreal.ca
Title
Cited by
Cited by
Year
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
AM van der Sloot, V Tur, E Szegezdi, MM Mullally, RH Cool, A Samali, ...
Proceedings of the National Academy of Sciences 103 (23), 8634-8639, 2006
2152006
Computational design of peptide ligands
P Vanhee, AM van der Sloot, E Verschueren, L Serrano, F Rousseau, ...
Trends in biotechnology 29 (5), 231-239, 2011
1792011
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line–derived neurotrophic factor
I Plaza Menacho, R Koster, AM van der Sloot, WJ Quax, J Osinga, ...
Cancer research 65 (5), 1729-1737, 2005
1082005
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
CR Reis, AM Van Der Sloot, A Natoni, E Szegezdi, R Setroikromo, ...
Cell death & disease 1 (10), e83-e83, 2010
982010
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design
V Tur, AM van der Sloot, CR Reis, E Szegezdi, RH Cool, A Samali, ...
Journal of biological chemistry 283 (29), 20560-20568, 2008
832008
A Novel Genetic Selection System for Improved Enantioselectivity of Bacillus subtilis Lipase A
YL Boersma, MJ Dröge, AM van der Sloot, T Pijning, RH Cool, ...
ChemBioChem 9 (7), 1110-1115, 2008
822008
A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome
JEH Bergman, N Janssen, AM van der Sloot, HEK de Walle, J Schoots, ...
Human mutation 33 (8), 1251-1260, 2012
802012
Engineering of weak helper interactions for high-efficiency FRET probes
R Grünberg, JV Burnier, T Ferrar, V Beltran-Sastre, F Stricher, ...
Nature methods 10 (10), 1021-1027, 2013
792013
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity
L O'Leary, AM van der Sloot, CR Reis, S Deegan, AE Ryan, SPS Dhami, ...
Oncogene 35 (10), 1261-1270, 2016
762016
Stabilization of TRAIL, an all-β-sheet multimeric protein, using computational redesign
AM van der Sloot, MM Mullally, G Fernandez-Ballester, L Serrano, ...
Protein Engineering Design and Selection 17 (9), 673-680, 2004
502004
Loop grafting of Bacillus subtilis lipase A: inversion of enantioselectivity
YL Boersma, T Pijning, MS Bosma, AM van der Sloot, LF Godinho, ...
Chemistry & biology 15 (8), 782-789, 2008
492008
Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants
C Xu, D Cassatella, AM van der Sloot, R Quinton, M Hauschild, ...
Genetics in medicine 20 (8), 872-881, 2018
472018
An improved understanding of TNFL/TNFR interactions using structure-based classifications
C Magis, AM van der Sloot, L Serrano, C Notredame
Trends in biochemical sciences 37 (9), 353-363, 2012
462012
Building blocks for protein interaction devices
R Grünberg, TS Ferrar, AM van der Sloot, M Constante, L Serrano
Nucleic acids research 38 (8), 2645-2662, 2010
452010
Binding of phage displayed Bacillus subtilis lipase A to a phosphonate suicide inhibitor
MJ Dröge, CJ Rüggeberg, AM van der Sloot, J Schimmel, DS Dijkstra, ...
Journal of biotechnology 101 (1), 19-28, 2003
452003
Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development
S Jacques, AM van der Sloot, C C. Huard, J Coulombe-Huntington, ...
Genetics 214 (4), 1103-1120, 2020
422020
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors
CR Reis, AM van der Sloot, E Szegezdi, A Natoni, V Tur, RH Cool, ...
Biochemistry 48 (10), 2180-2191, 2009
422009
Protein design with fragment databases
E Verschueren, P Vanhee, AM Van Der Sloot, L Serrano, F Rousseau, ...
Current opinion in structural biology 21 (4), 452-459, 2011
402011
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL
E Szegezdi, AM Van Der Sloot, D Mahalingam, L O'Leary, RH Cool, ...
Molecular & Cellular Proteomics 11 (3), 2012
332012
Targeting AML through DR4 with a novel variant of rhTRAIL
E Szegezdi, CR Reis, AM Sloot, A Natoni, A O’Reilly, J Reeve, RH Cool, ...
Journal of cellular and molecular medicine 15 (10), 2216-2231, 2011
332011
The system can't perform the operation now. Try again later.
Articles 1–20